Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retraction notice to "Cladophialophora bantiana metabolites are efficient in the larvicidal and ovicidal control of Aedes aegypti, and Culex quinquefasciatus and have low toxicity in zebrafish embryo" [Sci. Total Environ. 852 (2022) 158502].
Ragavendran C, Balasubramani G, Tijo C, Manigandan V, Kweka EJ, Karthika P, Sivasankar P, Thomas A, Natarajan D, Nakouti I, Malafaia G. Ragavendran C, et al. Among authors: thomas a. Sci Total Environ. 2024 Nov 22:177659. doi: 10.1016/j.scitotenv.2024.177659. Online ahead of print. Sci Total Environ. 2024. PMID: 39580259 No abstract available.
SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
Chun HM, Osawe S, Adams-Dabban S, Favaloro J, Iriemenam NC, Dirlikov E, Martin D, Milligan K, Abutu A, Okunoye O, Okoli M, Akanbi O, Akinmulero O, Okonkwo R, Oyedele O, Greby S, Abimiku A, Okoye MIJ, Shiraishi RW, Adegoke D, Bello M, Villeng F, Item II, Gabo S, Abubakar A, Thomas A, Olaleye T, Awala S, Nwatu F, Ugboaja B, Udoh I, Akayi L, Dattijo J, Adenekan T, Aminu-Alhaji A, Ezeuko I; Nigeria SARS-CoV-2 Serosurvey Among PLHIV Working Group, Nigeria SARS-CoV-2 Serosurvey Among PLHIV Working Group. Chun HM, et al. Among authors: thomas a. Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309. Online ahead of print. Int J Infect Dis. 2024. PMID: 39579925 Free article.
ENaC contributes to macrophage dysfunction in cystic fibrosis.
Moran J, Pugh C, Brown N, Thomas A, Zhang S, McCauley E, Cephas A, Shrestha CL, Partida-Sanchez S, Bai S, Bruscia E, Kopp BT. Moran J, et al. Among authors: thomas a. bioRxiv [Preprint]. 2024 Nov 8:2024.11.06.622340. doi: 10.1101/2024.11.06.622340. bioRxiv. 2024. PMID: 39574739 Free PMC article. Preprint.
Pretreatment factors associated with symptomatic stroke in Moyamoya disease patients: A multicenter study.
Musmar B, Roy JM, Salim HA, Kaul A, Atallah E, Naamani KE, Chen CJ, Jabre R, Saad H, Grossberg JA, Dmytriw AA, Patel AB, Khorasanizadeh M, Ogilvy CS, Thomas AJ, Monteiro A, Siddiqui A, Cortez GM, Hanel RA, Porto G, Spiotta AM, Piscopo AJ, Hasan DM, Ghorbani M, Weinberg J, Nimjee SM, Bekelis K, Salem MM, Burkhardt JK, Zetchi A, Matouk C, Howard BM, Lai R, Du R, Abbas R, Sioutas GS, Amllay A, Munoz A, Herial NA, Tjoumakaris SI, Gooch MR, Rosenwasser RH, Jabbour P. Musmar B, et al. Among authors: thomas aj. J Clin Neurosci. 2024 Nov 20;130:110922. doi: 10.1016/j.jocn.2024.110922. Online ahead of print. J Clin Neurosci. 2024. PMID: 39571479
Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study.
Tyrer F, Gharibzadeh S, Gillies C, Lawson C, Routen A, Islam N, Razieh C, Zaccardi F, Yates T, Davies MJ, Brightling CE, Chalmers JD, Docherty AB, Elneima O, Evans RA, Greening NJ, Harris VC, Harrison EM, Ho LP, Horsley A, Houchen-Wolloff L, Leavy OC, Lone NI, Marks M, McAuley HJC, Poinasamy K, Quint JK, Raman B, Richardson M, Saunders R, Sereno M, Shikotra A, Singapuri A, Wain LV, Khunti K; PHOSP‐COVID Study Collaborative Group. Tyrer F, et al. Diabetes Obes Metab. 2024 Nov 20. doi: 10.1111/dom.16071. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 39563623
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Russell NH, Thomas A, Hills RK, Thomas I, Gilkes A, Almuina NM, Burns S, Marsh L, Vyas P, Metzner M, McCarthy N, Andrew G, Byrne J, Sellar RS, Kelly R, Cahalin P, Overgaard UM, Mehta P, Dennis M, Knapper S, Freeman SD. Russell NH, et al. Among authors: thomas a. J Clin Oncol. 2024 Nov 18:JCO2400259. doi: 10.1200/JCO.24.00259. Online ahead of print. J Clin Oncol. 2024. PMID: 39556780
9,902 results